REFERENCE
1. Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematology Am Soc Hematol Educ Program. 2013;2013:605-611.
2. Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.
3. Pan H, Feng DN, Song L, et al. Acute myeloid leukemia following etoposide therapy for EBV-associated hemophagocytic lymphohistiocytosis: a case report and a brief review of the literature. BMC Pediatr. 2016;16:116
4. Sathiyamoorthy S, Shad A, Ozdemirli M. Acute promyelocytic leukemia following chemotherapy for EBV-associated hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2011;56(5):850-852.
5. Shamsian BS, Gharib A, Rezaei N, et al. Development of secondary T-cell acute lymphoblastic leukemia in a child with hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2010;55(4):725-726.
6. Hijiya N, Schultz KR, Metzler M, et al. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood. 2016;127(4):392-399.
7. Hijiya N, Millot F, Suttorp M. Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions. Pediatr Clin North Am. 2015;62(1):107-119.
8. Yang LH, Su P, Luedke C, et al. Chronic Myeloid Leukemia Following Treatment for Primary Neoplasms or Other Medical Conditions. Am J Clin Pathol. 2018;150(3):246-258.
9. Koptyra M, Cramer K, Slupianek A, et al. BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress. Leukemia. 2008;22(10):1969-1972.
10. Autore F, Sorà F, Chiusolo P, et al. ’Secondary chronic myeloid leukemia’: comparison between patients previously exposed or not to chemo- and/or radiotherapy. Leuk Lymphoma. 2019;60(14):3584-3586.
11. Ezoe S. Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health. 2012;9(7):2444-2453.
12. RamaChandran S, Ariffin H. Secondary acute myeloid leukemia after etoposide therapy for haemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2009;53(3):488-490.
13. Smyth MJ, Thia KY, Street SE, et al. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med. 2000;192(5):755-760.
14. Canna SW, Marsh RA. Pediatric hemophagocytic lymphohistiocytosis. Blood. 2020;135(16):1332-1343.
15. Chang TY, Jaffray J, Woda B, et al. Hemophagocytic lymphohistiocytosis with MUNC13-4 gene mutation or reduced natural killer cell function prior to onset of childhood leukemia. Pediatr Blood Cancer. 2011;56(5):856-858.
16. Džoljić E, Stošić-Opinćal T, Skender-Gazibara M, et al. Primary lymphoma of the brain in a young man whose brother died of hemophagocytic lymphohistiocytosis: case report. Srp Arh Celok Lek. 2015;143(1-2):63-67.
17. Rudd E, Göransdotter Ericson K, Zheng C, et al. Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignancies. J Med Genet. 2006;43(4):e14.
18. Kuan JW, Su AT, Leong CF, et al. Systematic review of pre-clinical chronic myeloid leukaemia [published correction appears in Int J Hematol. 2018 Nov 7;:]. Int J Hematol. 2018;108(5):465-484.
19. Morita K, Nakamura F, Taoka K, et al. Incidentally-detected t(9;22)(q34;q11)/BCR-ABL1- positive clone developing into chronic phase chronic myeloid leukaemia after four years of dormancy. Br J Haematol. 2016;174(5):815-817.
TABLE1 Laboratory results from the hematology department